ArriVent BioPharma Q3 2026 earnings

AVBP · 2026-11-09 16:05 AMC ET · 8-K on SEC

Operating loss narrowed sequentially and year-over-year, driven by lower R&D and G&A expenses and a modest increase in collaboration revenue, though the company reported a net loss of $40.3 million.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$5,000++Ex. 99.1, income statement
EPS (GAAP)-$0.81++Ex. 99.1, share information
Net income-$40,313++Ex. 99.1, income statement
Adj. EBITDA-$40,313++Ex. 99.1, income statement
Adj. EBITDA margin-806.3%++Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $48,376 (+26.3% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge No reconciliation provided; Net loss used as proxy for Adj. EBITDA.

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$113,583$154,682$45,540-26.6%
Short-term investments$279,640$218,437$267,281+28.0%
Weighted-average shares outstanding49,526,35647,606,85741,912,905+4.0%

Guidance

not stated in the 8-K

What drove it

  • Revenue story Collaboration revenue of $5,000 was recorded for the quarter, compared to $— in the prior year.
  • EPS story Net loss per share improved to -$0.81 from -$0.83 in the prior year, driven by lower operating expenses and a slight increase in weighted-average shares.
  • One-off check None stated.

The good

  • Operating loss narrowed sequentially to $43.4 million from $52.7 million in Q2.
  • Operating loss narrowed year-over-year to $43.4 million from $38.3 million in Q3 2025.
  • Cash and cash equivalents increased to $113.6 million from $45.5 million at the start of the year.
  • Short-term investments increased to $279.6 million from $267.3 million at the start of the year.

The bad

  • Net loss increased sequentially to $40.3 million from $49.9 million in Q2.
  • R&D expenses increased sequentially to $38.9 million from $42.3 million in Q2.
  • G&A expenses increased sequentially to $9.5 million from $10.4 million in Q2.
  • FURVENT trial did not meet its primary endpoint.

The ugly

  • none

Open questions

  • The filing does not disclose the specific terms or value of the collaboration revenue.
  • The filing does not disclose the specific reasons for the sequential increase in R&D and G&A expenses.
  • The filing does not disclose the specific reasons for the sequential increase in net loss.
Full release

ArriVent BioPharma (AVBP) earnings release, November 9, 2026

ArriVent BioPharma, Inc. (AVBP) · Form 8-K, Item 2.02 · Filed · SEC filing

ArriVent BioPharma Reports Third Quarter 2026

Financial Results

NEWTOWN SQUARE, PA, November 9, 2026 (GLOBE

NEWSWIRE) --

ArriVent BioPharma, Inc.

(Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30,

2026, and highlighted recent Company progress.

“Enrollment remains on track for our global

Phase 3 ALPACCA trial in first line EGFR PACC mutant NSCLC patients. While FURVENT did not meet its primary endpoint, firmonertinib demonstrated clear antitumor activity, with an efficacy and safety profile consistent with prior studies. We are conducting a detailed review of the

FURVENT study to better understand the totality of the data.,” said Bing Yao, Ph.D., CEO of ArriVent. “Our antibody-drug conjugate

(ADC) portfolio is also advancing, with initial ARR-217 data showing promising antitumor activity and a manageable safety profile in colorectal cancer. In addition, we dosed the first patient in a Phase 1 study of ARR-002. We are encouraged by the momentum across our pipeline and excited about the opportunity to advance these programs toward new potential treatment options for patients with significant unmet needs.”

Third Quarter 2026 and Recent Highlights

Firmonertinib

ADC Pipeline

Corporate

Upcoming Milestones

2026 Financial Results

About ArriVent

ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of next-generation antibody drug conjugates, through approval and commercialization.

About Firmonertinib

Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is approved in

China for first-line advanced non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or L858R mutations and for patients with previously treated locally advanced or metastatic NSCLC with EGFR T790M mutation, otherwise known as EGFR classical mutations. Firmonertinib is also approved in China for NSCLC with EGFR exon 20 insertion mutations in patients who had progressed during/after platinum chemotherapy or were intolerant to platinum chemotherapy.

Firmonertinib was granted U.S. Food and Drug Administration

(FDA) Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous

NSCLC with EGFR exon 20 insertion mutations. Firmonertinib was also granted U.S. FDA Orphan Drug Designation for the treatment of NSCLC with EGFR mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations.

Firmonertinib is currently being studied in a global Phase 3 study in first line NSCLC patients with EGFR PACC mutations (ALPACCA; NCT07185997).

About EGFR mutant NSCLC

Globally, lung cancer is the leading cause of cancer-related deaths among men and women. NSCLC is the predominant subtype of lung cancer, accounting for approximately 85% of all cases.

Mutational activation of the EGFR is a frequent and early event in the development of NSCLC. EGFR mutations are divided into classical and uncommon. EGFR exon 20 insertion mutations are a group of uncommon EGFR mutations and constitute approximately 9% of all EGFR mutations.

PACC mutations are another group of uncommon EGFR mutations and represent approximately 12% of all EGFR mutations. Patients with NSCLC whose tumors harbor uncommon EGFR mutations have significantly lower life expectancy with available therapies and represent an area of unmet medical need.

About EGFR PACC mutations

P-loop and αC-helix compressing (PACC) EGFR mutations are a distinct set of approximately 70 mostly missense activating mutations within the kinase domain of EGFR. They are similar to exon 20 insertion mutations in narrowing the drug binding pocket to affect tyrosine kinase inhibitor activity. PACC mutations are diagnosed through commercially available NGS and most PCR tests. Patients with PACC mutations have limited treatment options, and there is no broadly utilized standard of care treatment for first-line PACC mutant patients.

About ALPACCA

ALPACCA is a global, pivotal 2 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with PACC mutations being conducted jointly with our partner Allist (NCT07185997). The ALPACCA trial is evaluating firmonertinib 240 mg once daily versus investigator’s choice of osimertinib or afatinib in first-line patients with EGFR PACC mutant NSCLC. The 240 mg dose of firmonertinib was selected for pivotal development based on compelling data showing a 16-month median PFS and a confirmed 68% ORR by BICR in the FURTHER trial (NCT05364073).

The primary endpoints of this study are ORR and PFS by BICR per RECIST.

About ARR-217

ARR-217 (also known as MRG007) is a cadherin-17

(CDH17) targeted ADC, with a glycan-linked, exatecan-based payload. CDH17 is a membranous cell adhesion molecule and is frequently overexpressed in colorectal cancer (CRC) and several other gastrointestinal (GI) cancers, with limited expression in normal intestinal tissue and pancreatic duct. The differential expression profile in tumor versus normal tissue makes it an attractive target for antibody-drug conjugate (ADC)... (truncated)ted in a multi-center, Phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics in patients with unresectable locally advanced or metastatic solid tumors (NCT07066657).

About ARR-002

ARR-002 (also known as AV-P138-ADC) is a first-in-class,

Mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NaPi2b) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4. Both these cell surface antigens are expressed in solid tumors including ovarian and endometrial cancers with limited expression in normal tissues, making them ideal co-targets. ARR-002 is currently being evaluated in a multi-center, Phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics in patients with ovarian and endometrial cancers (NCT07755436).

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited) (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Collaboration revenue5,000$—5,000$—
Operating expenses:
Research and development38,89732,167118,853121,176
General and administrative9,4796,14928,32417,535
Total operating expenses48,37638,316147,177138,711
Operating loss-43,376-38,316-142,177-138,711
Interest and investment income3,0633,3388,6517,947
Net loss-40,313-34,978-133,526-130,764
Unrealized gain (loss) on marketable securities-199226-480419
Total other comprehensive gain (loss)-199226-480419
Total comprehensive loss-40,512-34,752-134,006-130,345
Share information:
Net loss per share attributable to common stockholders, basic and diluted-0.81-0.83-2.82-3.54
Weighted-average shares of common stock outstanding, basic and diluted49,526,35641,912,90547,425,42436,968,978

Balance Sheet

September 30, — BALANCE SHEETS (in thousands, except share and per share data) (Unaudited)

September 30, – 2026December 31, – 2025
Current assets:
Cash and cash equivalents113,58345,540
Short-term investments279,640267,281
Prepaid expenses and other current assets23,39220,076
Total current assets416,615332,897
Right of use assets – operating leases30213
Deferred offering costs3869
Other assets134190
Total assets417,089333,169
Current liabilities:
Accounts payable2,6155,934
Accrued expenses20,74219,997
Operating lease liabilities25614
Total liabilities23,61325,945
Stockholders’ equity:
Common stock $0.0001 par value, 200,000,000 shares authorized; 51,212,170 and 42,452,251 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively54
Additional paid-in capital932,104711,847
Accumulated deficit-538,167-404,641
Accumulated other comprehensive income (loss)-46614
Total stockholders’ equity393,476307,224
Total liabilities and stockholders’ equity417,089333,169

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities

Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, cash runway, estimates of our addressable market, activity of our product candidates compared to available therapies, anticipated clinical milestones, the timing of our planned enrollment of the global pivotal Phase 3 study of firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR PACC mutations, the advancement of the Phase 1 study for ARR-217 in gastrointestinal tumors and the timing of presentation of data from that study, the timing of the advancement of the Phase 1 study for ARR-002, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,”

“estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,”

“project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on

March 5, 2026, and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.